Treatment of Hemophagocytic Lymphohistiocytosis (HLH) Triggered by Malaria
Diagnostic Considerations
- The diagnosis of HLH may be confirmed by the presence of 5 of 8 HLH-2004 criteria, which is often associated with markedly elevated ferritin levels, soluble CD25 levels, and abnormal complete blood counts in patients with malaria 1
Treatment Algorithm for Malaria-Associated HLH
- The American Society of Hematology recommends administering appropriate antimalarial therapy based on Plasmodium species and resistance patterns, and adding corticosteroids to control hyperinflammation in patients with malaria-associated HLH 1
- Consider IV immunoglobulin up to 1.6 g/kg in split doses over 2-3 days for anti-inflammatory effects in patients with malaria-associated HLH 1, 4
Treatment of Severe or Refractory Cases
- Initiate etoposide according to modified HLH-94 protocol for patients with severe HLH presenting with imminent organ failure, with a recommended dose reduction if renal function is impaired 1, 5
- Weekly reevaluation of the need for continued etoposide therapy is recommended for patients with severe HLH 5, 4
Monitoring and Follow-up
- Regularly monitor ferritin, soluble CD25, cell counts, and liver function tests to assess treatment response in patients with malaria-associated HLH 4
- Vigilantly monitor for secondary infections, which are a major cause of mortality in HLH patients, and consider antimicrobial prophylaxis against Pneumocystis jirovecii and fungi for patients requiring immunosuppressive treatment 4, 6